Gamco Investors INC. ET AL Increases Stock Holdings in Evolent Health, Inc $EVH

Key Points

• Gamco Investors INC. ET AL increased its stake in Evolent Health, Inc by 25.6%, owning a total of 247,500 shares valued at approximately $2.34 million.
• Several large investors have significantly increased their holdings in Evolent Health in the past quarter, with Cadian Capital Management LP leading with a new stake valued at about $58.8 million.
• In its recent earnings report, Evolent Health recorded a revenue of $444.33 million, which was below analysts' expectations of $459.43 million, resulting in a negative net margin of -5.94%.

Gamco Investors INC. ET AL raised its stake in Evolent Health, Inc (NYSE:EVH - Free Report) by 25.6% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 247,500 shares of the technology company's stock after buying an additional 50,400 shares during the quarter. Gamco Investors INC. ET AL owned approximately 0.21% of Evolent Health worth $2,344,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in EVH. Cadian Capital Management LP purchased a new stake in Evolent Health in the 4th quarter valued at $58,781,000. Sea Cliff Partners Management LP acquired a new position in shares of Evolent Health in the 4th quarter valued at $9,338,000. Millennium Management LLC lifted its stake in shares of Evolent Health by 134.7% in the 4th quarter. Millennium Management LLC now owns 1,255,446 shares of the technology company's stock valued at $14,124,000 after purchasing an additional 720,625 shares during the last quarter. Hudson Bay Capital Management LP lifted its stake in shares of Evolent Health by 146.0% in the 4th quarter. Hudson Bay Capital Management LP now owns 1,013,267 shares of the technology company's stock valued at $11,399,000 after purchasing an additional 601,436 shares during the last quarter. Finally, Federated Hermes Inc. lifted its stake in Evolent Health by 122.9% during the 1st quarter. Federated Hermes Inc. now owns 1,015,444 shares of the technology company's stock worth $9,616,000 after acquiring an additional 559,837 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Truist Financial increased their target price on Evolent Health from $14.00 to $16.00 and gave the stock a "buy" rating in a research note on Thursday, July 17th. JMP Securities reaffirmed a "market outperform" rating and issued a $13.00 price target on shares of Evolent Health in a research report on Friday, June 20th. Needham & Company LLC reaffirmed a "buy" rating and issued a $15.00 price target on shares of Evolent Health in a research report on Tuesday, May 13th. UBS Group increased their price target on Evolent Health from $14.00 to $15.00 and gave the company a "buy" rating in a research report on Friday, May 9th. Finally, Piper Sandler increased their price target on Evolent Health from $16.00 to $18.00 and gave the company an "overweight" rating in a research report on Thursday, August 28th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Evolent Health presently has a consensus rating of "Buy" and an average price target of $18.07.

Evolent Health Stock Performance

NYSE:EVH traded down $0.11 during mid-day trading on Wednesday, reaching $9.50. 273,962 shares of the stock were exchanged, compared to its average volume of 2,672,439. The company has a 50 day simple moving average of $10.12 and a 200-day simple moving average of $9.54. The stock has a market capitalization of $1.12 billion, a P/E ratio of -5.90 and a beta of 0.73. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 0.72. Evolent Health, Inc has a 1 year low of $7.06 and a 1 year high of $31.80.

Evolent Health (NYSE:EVH - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The technology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.20). The firm had revenue of $444.33 million for the quarter, compared to analysts' expectations of $459.43 million. Evolent Health had a positive return on equity of 1.83% and a negative net margin of 5.94%.The company's quarterly revenue was down 31.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.30 EPS. Evolent Health has set its Q3 2025 guidance at EPS. Analysts anticipate that Evolent Health, Inc will post 0.08 earnings per share for the current fiscal year.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.